Xoma 
Welcome,         Profile    Billing    Logout  
 40 Products   215 Diseases  40 Products   125 Trials   4697 News 
197 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gevokizumab (VPM087) / Novartis
NCT02366260: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Recruiting
3
5
US
Gevokizumab, Placebo
MedDerm Associates, XOMA (US) LLC
Pyoderma Gangrenosum
10/16
 
NCT03798626: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Active, not recruiting
1
167
Europe, Canada, Japan, US, RoW
Gevokizumab, VPM087, Bevacizumab, Modified FOLFOX6, oxaliplatin, leucovorin, 5-fluorouracil, FOLFIRI, irinotecan, leucovorin, 5-fluorouracil, Ramucirumab, Paclitaxel, Cabozantinib
Novartis Pharmaceuticals
Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
03/23
01/25
Ixinity (trenonacog alfa) / Medexus
2021-005356-10: A pivotal study of N-Acetyl-L-Leucine on Niemann-Pick disease type C

Ongoing
3
53
Europe, RoW
N-acetyl-L-leucine, IB1001, Granules for oral suspension in sachet
IntraBio Ltd, IntraBio Ltd
Niemann-Pick Disease type C (NPC) Niemann-Pickovu chorobu typu C, Niemann-Pick Disease type C (NPC) Niemann-Pickovu chorobu typu C, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
NCT05163288: A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

Active, not recruiting
3
53
Europe, US, RoW
N-Acetyl-L-Leucine, IB1001, Placebo
IntraBio Inc
Niemann-Pick Disease, Type C
06/23
11/24
NCT06673056: A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

Not yet recruiting
3
60
Europe, US
N-Acetyl-L-Leucine, IB1001, levacetylleucine, Placebo
IntraBio Inc
Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
12/27
06/28
NCT03759639: N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)

Completed
2
33
Europe, US
IB1001, N-Acetyl-L-Leucine
IntraBio Inc
Niemann-Pick Disease, Type C
11/22
11/22
2018-004331-71: To demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning and quality of life in patients with Niemann-Pick Type C disease (NPC).

Not yet recruiting
2
39
Europe, RoW
N-Acetyl-L-Leucine, IB1001, Powder for oral suspension, Granules for oral suspension
IntraBio Ltd, IntraBio Ltd,
To demonstrate that N-Acetyl-L-Leucine is effective in improvingsymptoms, functioning, and quality of life in patients withNiemann-Pick Type C disease (NPC)., Niemann-Pick Type C (NPC) is a rare inherited neurodegenerative disease that occurs when the cerebellum becomes inflamed or damaged., Diseases [C] - Nervous System Diseases [C10]
 
 
2018-004406-25: To demonstrate that N-Acetyl-L-Leucine is effective in improving symptoms, functioning and quality of life in patients with GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease).

Not yet recruiting
2
39
Europe, RoW
N-Acetyl-L-Leucine, IB1001, Powder for oral suspension, Granules for oral suspension
IntraBio Ltd, IntraBio Ltd,
To demonstrate that N-Acetyl-L-Leucine is effective in improvingsymptoms, functioning, and quality of life in patients GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)., Tay–Sachs disease (α-mutations) and Sandhoff disease (β-mutations) are neurovisceral autosomal-recessive inherited metabolic, lysosomal storage disorder (LSD)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT03759665: N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)

Completed
2
30
Europe, US
IB1001, N-Acetyl-L-Leucine
IntraBio Inc
GM2 Gangliosidosis, Tay-Sachs Disease, Sandhoff Disease
01/23
01/23
NCT03759678 / 2018-004407-39: N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

Recruiting
2
39
Europe, US
IB1001, N-Acetyl-L-Leucine
IntraBio Inc
Ataxia Telangiectasia, Louis Bar Syndrome
12/24
03/25
Dsuvia (sufentanil sublingual) / Alora Pharma
NCT04716413: Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment

Terminated
4
3
US
Dsuvia
Montefiore Medical Center
Acute Pain
11/22
11/22
NCT05307341: Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA)

Recruiting
4
100
US
sufentanil, sufentanil (DSUVIA)
More Foundation
Pain
06/23
06/23
DEEP, NCT05288348: DSUVIA Early Evaluation of Pain Trial

Completed
3
150
US
Sufentanil 30 MCG Sublingual Tablet, standard care pain treatment
Frank Guyette, United States Department of Defense
Traumatic Injury
01/24
01/24
NCT05388188: DSUVIA in Patients With SCD VOC Present in the ED

Recruiting
N/A
100
US
sublingual sufentanil, Dsuvia Sublingual Product
Jason Wilson
Sickle-Cell Disease With Crisis
04/23
12/23
Ojemda (tovorafenib) / Day One Biopharma
LOGGIC, NCT05566795 / 2022-001363-27: DAY101 Vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy (/FIREFLY-2)

Recruiting
3
400
Europe, Canada, US, RoW
Tovorafenib, DAY101, Ojemda, Chemotherapeutic Agent, COG-V/C, SIOPe-LGG-V/C, VBL
Day One Biopharmaceuticals, Inc., SIOPe Brain Tumor Group LOGGIC Consortium
Low-grade Glioma
02/26
03/30
2020-003657-30: A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain Cancer

Ongoing
2
60
Europe
DAY101, Tablet
DOT Therapeutics-1 Inc. (Day One), DOT Therapeutics-1 Inc. (Day One)
BRAF-Altered, Recurrent or Progressive Low-Grade Glioma in pediatric patients, Brain tumor in children, Diseases [C] - Cancer [C04]
 
 
FIREFLY 1, NCT04775485: A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Recruiting
2
140
Europe, Canada, US, RoW
DAY101
Day One Biopharmaceuticals, Inc., Pacific Pediatric Neuro-Oncology Consortium
Low-grade Glioma, Advanced Solid Tumor
12/22
06/24
NCT05287295: A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Not yet recruiting
2
28
NA
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Tovorafenib, BIIB-024, DAY 101, DAY-101, DAY101, MLN-2480, MLN2480, pan-RAF Kinase Inhibitor DAY101, TAK-580, TAK580
Children's Oncology Group
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
05/25
05/25
NCT05828069: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
2
48
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Lumbar Puncture, LP, Spinal Tap, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Tovorafenib, BIIB-024, DAY 101, DAY-101, DAY101, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK-580, TAK580
National Cancer Institute (NCI)
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
05/25
05/25
PNOC029, NCT05465174: Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
2
56
US
Nivolumab, Opdivo, Tovorafenib, DAY101, TAK580, AMG-2112819, BSK1369
Sabine Mueller, MD, PhD, Bristol-Myers Squibb, Day One Biopharmaceuticals, Inc.
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
03/27
03/28
FIRELIGHT-1, NCT04985604: Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Active, not recruiting
1/2
168
Europe, Canada, US, RoW
Tovorafenib, Pimasertib
Day One Biopharmaceuticals, Inc.
Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
07/25
12/25
VICTORY, NCT06381570: Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Recruiting
1
57
Canada
Tovorafenib, Vinblastine
Daniel Morgenstern, The Hospital for Sick Children
Low-grade Glioma
03/26
03/29
PNOC014, NCT03429803: DAY101 In Gliomas and Other Tumors

Active, not recruiting
1
44
US
DAY101, MLN2480, TAK-580
Karen D. Wright, MD, PLGA Fund at Pediatric Brain Tumor Foundation, National Cancer Institute (NCI), Pacific Pediatric Neuro-Oncology Consortium, Team Jack Foundation, Day One Biopharmaceuticals, Inc.
Low-grade Glioma
12/24
12/24
NCT05760586: Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Approved for marketing
N/A
NA
Tovorafenib, DAY101
Day One Biopharmaceuticals, Inc.
Low-grade Glioma
 
 
vidutolimod (CMP-001) / Regeneron
NCT05059522 / 2021-002457-29: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruiting
3
67
Europe, Canada, Japan, US, RoW
Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600
Pfizer
Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
09/26
09/26
CMP-001-011, NCT04695977: CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Terminated
2/3
20
US
CMP-001, vidutolimod, Nivolumab, OPDIVO
Regeneron Pharmaceuticals, Bristol-Myers Squibb
Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
07/24
07/24
NCT03618641: CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease

Completed
2
34
US
CMP-001, Nivolumab
Diwakar Davar, Checkmate Pharmaceuticals
Melanoma, Lymph Node Cancer
08/20
12/23
NCT04807192: CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)

Recruiting
2
40
Europe
stereotactic body radiotherapy, CMP-001
Centre Hospitalier Universitaire Vaudois
Triple Negative Breast Cancer
09/23
12/25
CMP-001-007, NCT04633278: CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated
2
24
US
CMP-001, vidutolimod, Pembrolizumab, Keytruda
Regeneron Pharmaceuticals
Squamous Cell Carcinoma of Head and Neck
01/24
01/24
NCT04698187: CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Terminated
2
44
US
CMP-001, vidutolimod, Nivolumab, OPDIVO
Regeneron Pharmaceuticals, Bristol-Myers Squibb
Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
02/24
02/24
NCT04708418: A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma

Suspended
2
60
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, QL2107, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery, VLP-encapsulated TLR9 Agonist CMP-001
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
06/25
06/25
NCT04916002: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Terminated
2
77
US, RoW
vidutolimod, CMP-001, cemiplimab, Libtayo, REGN2810
Regeneron Pharmaceuticals
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
10/24
10/24
NCT05445609: Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Suspended
2
10
US
VLP-encapsulated TLR9 Agonist CMP-001,, ARB-1598, CMP-001, CYT 003, CYT-003, Nivolumab, 946414-94-4, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Emory University, National Cancer Institute (NCI), Prostate Cancer Foundation
Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
06/27
06/27
NCT04401995: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab

Completed
2
9
US
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Diwakar Davar, Checkmate Pharmaceuticals, CellSight Technologies, Inc.
Melanoma
08/24
08/24
NCT04387071: CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

Terminated
1/2
2
US
Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, Anti-OX40 Agonist Antibody INCAGN01949, Anti-OX40 Monoclonal Antibody INCAGN0194, INCAGN 1949, INCAGN-1949, INCAGN1949, Monoclonal Antibody INCAGN01949, NCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001, ARB-1598, CMP-001, CYT 003, CYT-003
University of Southern California, National Cancer Institute (NCI)
Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
12/22
12/22
JAVELIN Medley, NCT02554812 / 2015-002552-27: A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies

Calendar Jan 2024 - Dec 2024: From JAVELIN Medley trial in combination with utomilumab for NSCLC, melanoma and SCCHN
Checkmark JAVELIN Medley trial of Bavencio + PF-04518600 + utomilumab in advanced malignancies
Jan 2018 - Jan 2018: JAVELIN Medley trial of Bavencio + PF-04518600 + utomilumab in advanced malignancies
Checkmark Combination study with PF-05082566 for NSCLC
Sep 2015 - Sep 2015: Combination study with PF-05082566 for NSCLC
Terminated
1/2
409
Europe, Canada, Japan, US, RoW
Avelumab, MSB0010718C, Utomilumab, PF-05082566, PF-04518600, PD 0360324, CMP-001
Pfizer
Advanced Cancer
03/23
03/23
NCT03983668: CMP-001 for Relapsed and Refractory Lymphoma

Active, not recruiting
1/2
39
US
CMP-001, CYT003; QbG10; IND # 18627, Pembrolizumab, Keytruda
Umar Farooq, Checkmate Pharmaceuticals, Merck Sharp & Dohme LLC, University of Iowa
Lymphoma
04/25
04/26
CA209-991, NCT03507699: Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

Completed
1
19
RoW
Liver radiation therapy, Liver radiosurgery, Nivolumab Injection [Opdivo], Ipilimumab Injection [Yervoy], CMP-001
Sheba Medical Center, Checkmate Pharmaceuticals, Bristol-Myers Squibb
Colorectal Neoplasms Malignant, Liver Metastases
08/21
05/22
NCT06063746: Compassionate Use of Vidutolimod

Available
N/A
NA
Vidutolimod, CMP-001
Regeneron Pharmaceuticals
 
 
aldoxorubicin (INNO-206) / LadRx
QUILT-88, NCT04390399: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Checkmark Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Hourglass Jul 2021 - Sep 2021 : Anticipated enrollment of Cohort C in metastatic 3L pancreatic cancer
Active, not recruiting
2
328
US
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
ImmunityBio, Inc.
Pancreatic Cancer
10/25
10/25
QUILT-3.071, NCT03563157: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Active, not recruiting
1b/2
332
US
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
ImmunityBio, Inc.
Colorectal Cancer Metastatic, mCRC
12/22
12/22
QUILT-3.067, NCT03387085: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated
1/2
9
US
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
ImmunityBio, Inc.
Triple Negative Breast Cancer
09/20
01/24
NCT02570412: Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

No Longer Available
N/A
US
aldoxorubicin
CytRx
Sarcoma
 
 
Qinprezo (vosaroxin) / Denovo
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Recruiting
2/3
3100
Europe
Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax
University Hospital, Angers
Acute Myeloid Leukemia (AML)
07/25
01/32
VITAL, NCT02658487: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Active, not recruiting
2
42
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Vosaroxin, AG-7352, SNS-595, SPC 595, Voreloxin
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
04/19
09/24
2015-004066-28: A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15 Studie mit einem Dosisfindungsteil gefolgt von einem Phase II-Teil zu Vosaroxin in Kombination mit Azacitidin bei Patienten mit akuter myeloischer Leukämie und intermediärem bzw. ungünstigem genetischem Risiko oder myelodysplastischen Syndrom mit Exzess von Blasten (MDS-EB-2) (AMLSG 24-15)

Not yet recruiting
2
168
Europe
Azacitidine, Vosaroxin, not applicalbe, Powder for injection, Injection, Vidaza
University Hospital Ulm, SUNESIS PHARMACEUTICALS, INC, University Hospital Ulm
Patients with confirmed diagnosis of acute myeloid leukemia (WHO 2016) and intermediate or adverse genetic risk (according to 2017 ELN recommendations); or patients with myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) Patienten mit bestätigter Diagnose einer akuten myeloischen Leukämie (WHO 2016) und intermediärem oder ungünstigem genetischem Risiko (entsprechend den ELN Empfehlungen 2017); oder Patienten mit myelodysplastischem Syndrom mit Exzess von Blasten (MDS-EB-2), Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) Patienten mit Neu diagnostizierte akute myeloische Leukämie oder myelodysplastisches Syndrom mit Exzess von Blasten (MDS-EB-2), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01913951: Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Checkmark For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Jun 2017 - Jun 2017: For vosaroxin and azacitidine combination trial in myelodysplastic syndrome at EHA 2017
Checkmark ASH 2015
Dec 2015 - Dec 2015: ASH 2015
Completed
1
35
US
vosaroxin, voreloxin, Azacitidine, Vidaza, Ladakamycin
Washington University School of Medicine, Sunesis Pharmaceuticals
Myelodysplastic Syndromes
12/16
04/24
ficlatuzumab (AV-299) / LG Chem
FIERCE-HN, NCT06064877: A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Recruiting
3
410
Europe, Canada, US, RoW
Ficlatuzumab, AV-299, Cetuximab, Erbitux, Placebo
AVEO Pharmaceuticals, Inc.
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
08/27
11/27
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

No Longer Available
N/A
US
ficlatuzumab, AV-299, SCH 900105
AVEO Pharmaceuticals, Inc.
Mullerian Mixed Tumor of Ovary
 
 
Raptiva (efalizumab) / Roche, EMD Serono, Xoma
2007-001630-14: Safety and efficacy of efalizumab in combination with methotrexate in patients with severe psoriasis: a comparative study.

Ongoing
4
30
Europe
Raptiva, Raptiva
University Medical Centre St. Radboud, Department of Dermatology
Moderate to severe chronic plaque psoriasis
 
 
2007-001377-28: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™)

 
4
10
Europe
Raptiva 100 mg/ml powder and solvent for solution for injection, Raptiva 100 mg/ml powder and solvent for solution for injection
Merck Serono International S.A.
Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
 
07/09
2008-004721-41: Profil des populations leucocytaires chez les patients atteints de psoriasis répondeurs et non répondeurs au traitement par efaluzimab (anti-CD11A) : étude systémique et cutanée

Ongoing
4
30
Europe
RAPTIVA, RAPTIVA
CHU de Bordeaux
patients atteints de psoriasis modérés à sévère
 
 
PBF-680 / Palobiofarma
2021-001732-25: A clinical trial to assess the effect of PBF-680 in patients with moderate to severe Chronic Obstructive Pulmonar Disease on top of standard medication. Ensayo clínico para evaluar el efecto del PBF-680 en pacientes con Enfermedad Pulmonar Obstructiva Crónica de moderada a severa, conjuntamente con la medicación habitual.

Ongoing
2
102
Europe
PBF-680, Capsule, hard
Palobiofarma, S.L, Palobiofarma, S.L
Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD) Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave., Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD) Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Respire, NCT05262218: Therapeutic Effect of PBF-680 in Patients With COPD

Completed
2
174
Europe
PBF-680 10mg, Placebo
Palobiofarma SL, Scope International AG
COPD
02/24
04/24
acimtamig (AFM13) / Affimed
REDIRECT, NCT04101331 / 2019-001003-20: Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Completed
2
108
Europe, US, RoW
AFM13
Affimed GmbH
Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides
05/22
01/24
LuminICE-203, NCT05883449: Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL

Recruiting
2
154
US
AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
Affimed GmbH, Artiva Biotherapeutics, Inc.
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
04/26
11/27
NCI-2019-03536, NCT04074746: Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Active, not recruiting
1/2
30
US
Anti-CD30/CD16A Monoclonal Antibody AFM13, AFM13, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Genetically Engineered Lymphocyte Therapy
M.D. Anderson Cancer Center
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
04/25
04/25
tuparstobart (INCAGN2385) / Incyte
2021-005775-39: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Estudio an fase II, aleatorizado, doble ciego y multicéntrico de retifanlimab en combinación con INCAGN02385 e INCAGN02390 como tratamiento de primera línea en participantes con carcinoma escamoso de cabeza y cuello metastásico/recidivante .

Ongoing
2
162
Europe
Retifanlimab, INCMGA00012, INCAGN02385, INCAGN0290, Solution for infusion
Incyte Biosciences International Sarl, Incyte Biosciences International Sarl
In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN. En participantes con PD-L1 positivo y terapia sistémica R/M SCCHN sin tratamiento previo., In participants with biomarker positive and untreated advanced head and neck cancer En participantes con biomarcadores positivos y con cancer de cabeza y cuello avanzado no tratado., Diseases [C] - Cancer [C04]
 
 
Optimus, NCT04586244: An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Terminated
2
30
Europe, US
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Incyte Corporation
Urothelial Carcinoma
01/24
01/24
NCT05287113: Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
2
176
Europe, Canada, US, RoW
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Incyte Biosciences International Sàrl
Head and Neck Cancer
02/25
06/25
POD1UM-204, NCT04463771 / 2020-000496-20: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Active, not recruiting
2
206
Europe, US, RoW
retifanlimab, INCMGA00012, epacadostat, pemigatinib, INCAGN02385, INCAGN02390
Incyte Corporation, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Cancer
04/25
05/26
TRICK-MCC, NCT06056895: Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Recruiting
2
20
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Tuparstobart, Anti-LAG-3 Monoclonal Antibody INCAGN02385, Anti-LAG3 Monoclonal Antibody INCAGN02385, INCAGN 02385, INCAGN 2385, INCAGN02385, INCAGN2385, Verzistobart, Anti-TIM-3 Monoclonal Antibody INCAGN02390, INCAGN 02390, INCAGN-02390, INCAGN02390
University of Washington, Incyte Corporation
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
12/29
12/29
NCT04370704: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Active, not recruiting
1/2
61
US, RoW
INCAGN02385, INCAGN02390, INCMGA00012.
Incyte Corporation
Melanoma
08/25
08/25
NCT06290622: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Withdrawn
1
18
US
Retifanlimab, INCAGN02385, INCAGN02390
University of Alabama at Birmingham
Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular
06/26
01/28
nisevokitug (NIS793) / Novartis
2021-000591-10: Study of efficacy and safety of NIS793 in combination with standard of care (SOC) chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

Ongoing
3
490
Europe
nab-paclitaxel, gemcitabine, NIS793, Concentrate for solution for infusion, Powder for solution for infusion
Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Pancreatic ductal adenocarcinoma, Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
daNIS-2, NCT04935359 / 2021-000591-10: Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) -

Completed
3
511
Europe, Canada, Japan, US, RoW
NIS793, Nab-paclitaxel, Gemcitabine, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Pancreatic Ductal Adenocarcinoma
08/24
08/24
2021-000553-40: Study of NIS793 and other novel investigational combinations with SOC anti-cancer therapy for the second line treatment of mCRC Az NIS793 vizsgálata és egyéb új vizsgálati készítmények hagyományos rákellenes kezelésekkel való kombinációja az áttétes kolorektális rák (mCRC) másodvonalbeli kezeléseként

Ongoing
2
190
Europe
5-Fluorouracil, oxaliplatin, leucovorin, irinotecan, bevacizumab, NIS793, Concentrate for solution for infusion, Powder for solution for infusion
Novartis Pharma AG, Novartis Pharma AG
metastatic colorectal cancer (mCRC), colorectal cancer, Diseases [C] - Cancer [C04]
 
 
NCT05546411: A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Terminated
2
8
US
mFOLFIRINOX, 5-Fluorouracil (5-FU), Adrucil, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, Camptothecin-11, CPT-1, Leucovorin, Calcium Leucovorin, Citrovorum Factor, Folinic Acid, NIS793, Chemoradiation, Surgery
Kimberly Perez, MD, Novartis
Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
08/23
10/23
daNIS-1, NCT04390763 / 2020-000349-14: Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Terminated
2
164
Europe, US, RoW
NIS793, Spartalizumab, PDR001, gemcitabine, nab-paclitaxel, abraxane
Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
04/24
05/24
daNIS-3, NCT04952753 / 2021-000553-40: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Active, not recruiting
2
204
Europe, Canada, Japan, US, RoW
NIS793, Bevacizumab, Modified FOLFOX6, 5FU+Leucovorin+Oxaliplatin, FOLFIRI, 5FU+Leucovorin+Irinotecan, Tislelizumab, VDT482
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Colorectal Cancer
01/25
01/25
ADORE, NCT04097821 / 2019-000373-23: Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Calendar Jan 2024 - Dec 2024: From ADORE trial for myelofibrosis
Completed
1/2
45
Europe, Canada, RoW
Ruxolitinib, INC424, Jakavi, Siremadlin, HDM201, Crizanlizumab, SEG101, Sabatolimab, MBG453, Rineterkib, LTT462, NIS793
Novartis Pharmaceuticals
Myelofibrosis
05/23
08/24
NCT04810611: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Terminated
1
33
Europe, US, RoW
MBG453, sabatolimab, NIS793, canakinumab, ACZ885
Novartis Pharmaceuticals
Myelodysplastic Syndromes
04/24
04/24
NCT05417386: FOLFIRINOX + NIS793 in Pancreatic Cancer

Terminated
1
4
US
FOLFIRINOX, Oxaliplatin, Eloxatin, Leucovorin, Calcium Leucovorin, Citrovorum Factor, Folinic Acid, Irinotecan, Camptosar, Camptothecin-11, CPT-1, 5-Fluorouracil (5-FU), Adrucil, NIS793, Chemoradiation, Capecitabine, Xeloda, Radiation Therapy, Surgery
Colin D. Weekes, M.D., PhD, Novartis
Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
07/23
07/23
Vabysmo (faricimab-svoa) / Roche
ACTRN12623000215628: Assessing the Efficacy and Durability of Faricimab in Patients Currently Treated for Neovascular Age-Related Macular Degeneration.

Not yet recruiting
4
150
 
CUREOS, Roche
Neovascular Age-related Macular Degeneration
 
 
NCT05610488: Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept

Not yet recruiting
4
30
NA
FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO], Vabysmo
Vista Klinik
Diabetic Macular Edema
12/23
12/23
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Recruiting
4
446
Europe, Canada, US, RoW
Faricimab
McMaster University, Hoffmann-La Roche
Diabetic Macular Edema
08/26
08/26
FAN, NCT05941715: Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

Active, not recruiting
4
70
Europe
Aflibercept 40 MG/ML, Eylea®, Faricimab 120 MG/ML, Vabysmo®
Medical University of Graz
Neovascular Age-related Macular Degeneration
10/24
02/25
NCT06191094: Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Enrolling by invitation
4
100
US
Faricimab Injection, Vabysmo, sham treatment
University of Colorado, Denver
Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
01/25
01/27
NCT06683950: Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

Recruiting
4
40
RoW
Aflibercept 8mg
Kim's Eye Hospital
Age-related Macular Degeneration (ARMD)
12/25
05/26
NCT05224102: A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

Recruiting
4
218
US, RoW
Faricimab, VABYSMO™, RO6867461, RG7716
Genentech, Inc.
Diabetic Macular Edema
11/26
11/26
ChiCTR2400082177: An observational study of Faricimab in the treatment of neovascular age-related macular degeneration with refractory pigment epithelium detachment

Not yet recruiting
4
35
 
Accepting one intravitreal injection of 0.05ml Faricimab; Follow up is conducted once a month, and the researcher decides to evaluate based on the standard of repeated administration. At each subsequent follow-up point, the researcher evaluates whether to continue intraocular injection for the subject, which is 1+PRN
Shanghai General Hospital; Shanghai General Hospital, Self raised
wet age-related macular degeneration
 
 
BALATON, NCT04740905 / 2020-000440-63: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

Completed
3
553
Europe, Japan, US, RoW
Faricimab, VABYSMO®, faricimab-svoa, RO6867461, RG7716, Aflibercept, Eylea, Sham Procedure
Hoffmann-La Roche, Chugai Pharmaceutical
Macular Edema, Branch Retinal Vein Occlusion
07/22
06/23
COMINO, NCT04740931 / 2020-000441-13: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

Completed
3
729
Europe, Japan, US, RoW
Faricimab, VABYSMO®, faricimab-svoa, RG7716, RO6867461, Aflibercept, Eylea, Sham Procedure
Hoffmann-La Roche, Chugai Pharmaceutical
Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
08/22
07/23
Rhone-X, NCT04432831 / 2020-000402-29: A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

Completed
3
1479
Europe, Canada, Japan, US, RoW
Faricimab, RO6867461, RG7716, Sham Procedure
Hoffmann-La Roche
Diabetic Macular Edema
10/23
10/23
POYANG, NCT06176352: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Recruiting
3
280
Europe, RoW
Faricimab, VABYSMO®, faricimab-svoa, RO6867461, RG7716, Ranibizumab, Lucentis, Sham Procedure
Hoffmann-La Roche
Choroidal Neovascularization Secondary to Pathologic Myopia
02/26
11/26
AVONELLE-X, NCT04777201 / 2020-004523-16: A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants with Neovascular Age-Related Macular Degeneration

Completed
3
1036
Europe, Canada, Japan, US, RoW
Faricimab, RO6867461, RG7716, Sham Procedure
Hoffmann-La Roche
Neovascular Age-related Macular Degeneration
09/24
09/24
AL, NCT05844982: Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Recruiting
3
600
US
Faricimab, fluocinolone acetonide
Jaeb Center for Health Research, National Eye Institute (NEI), National Institutes of Health (NIH), Alimera Sciences, Genentech, Inc.
Radiation Retinopathy, Visual Impairment
12/29
12/29
AO, NCT05904028: Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Recruiting
3
600
Canada, US
Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule, Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule, Home OCT
Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation
Neovascular Age-related Macular Degeneration
07/27
07/27
NCT06572553: Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients

Recruiting
2/3
30
RoW
Faricimab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
08/24
08/24
MAGIC, NCT05681884: Safety and Efficacy of Faricimab in Patients With NPDR

Active, not recruiting
2
150
US
Faricimab
Greater Houston Retina Research, Genentech, Inc.
Non-Proliferative Diabetic Retinopathy
03/26
04/26
ChiCTR2400090827: A study of the safety, efficacy, and cost-effectiveness of using non-vitrectomised subretinal anti-VEGF injections to treat neovascular age-related macular degeneration

Not yet recruiting
1
80
 
A single non-vitrectomised subretinal Faricimab (6mg/0.05ml) injection at the start of treatment, then followed retreatment by intravitreal Faricimab (6mg/0.05ml) injections on a treat as needed (PRN) basis.; 3 loading doses of monthly intravitreal of Faricimab (6mg/0.01ml) followed retreatment by PRN basis.
Department of Ophthalmology and Visual Sciences, CUHK; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Principal Investigator
neovacular age-related macular degeneration (nAMD)
 
 
NCT06124677: Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments

Completed
N/A
46
Europe
Faricimab, Vabysmo (6 mg, 0.05 ml)
Rigshospitalet, Denmark
Neovascular Age-related Macular Degeneration
11/23
12/23
NCT06231121: Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

Completed
N/A
13
Europe
Faricimab, Vabysmo (6 mg, 0.05 ml)
Rigshospitalet, Denmark
Neovascular Age-related Macular Degeneration
01/24
01/24
FAR-WEST, NCT06271330: Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.

Not yet recruiting
N/A
100
Europe
Faricimab
Nantes University Hospital, Rennes University Hospital
AMD
04/25
09/26
NCT06439576: Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Recruiting
N/A
1000
RoW
Faricimab, VABYSMO®
Hoffmann-La Roche, Shanghai Roche Pharmaceutical Co., Ltd
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
11/27
11/27
NCT06680817: A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Not yet recruiting
N/A
850
NA
Faricimab, VABYSMO®, RO6867461, RG7716
Hoffmann-La Roche
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
06/27
06/28
VOYAGER, NCT05476926: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Recruiting
N/A
6000
Europe, Canada, Japan, US, RoW
Faricimab, VABYSMO™, RO6867461, RG7716, Port Delivery System with Ranibizumab, SUSVIMO™, RG6321
Hoffmann-La Roche
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
12/26
12/27
mezagitamab (TAK-079) / Takeda
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Completed
2
41
Europe, Japan, US, RoW
Placebo, TAK-079
Takeda
Primary Immune Thrombocytopenia
04/24
04/24
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated
1/2
27
Canada, US
TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Takeda
Relapsed and/or Refractory Multiple Myeloma (RRMM)
08/23
11/23
NCT03984097: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Active, not recruiting
1
50
US
TAK-079, Mezagitamab, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide
Takeda
Multiple Myeloma
02/25
02/25
 

Download Options